-transparent.png){kind=logo}
A comparative investigation of the antineoplastic activity of adriamycin and its derivative, N-trifluoroacetyladriamycin-14-valerate (AD 32), was conducted in murine tumor models employing different treatment schedules and injection routes. In all conditions tested, ie, ascitic and disseminated L1210 leukemia, ascitic LSTRA lymphoma, and advanced Lewis lung carcinoma, AD 32 was significantly more effective in terms of lifespan prolongation and induction of cures than optimal adriamycin treatments. As with adriamycin, AD 32 was ineffective on ic transplanted L1210 leukemia.
Related Publications
A Vecchi, and
M Cairo, and
A Mantovani, and
M Sironi, and
F Spreafico
June 1976,
Cancer research,
A Vecchi, and
M Cairo, and
A Mantovani, and
M Sironi, and
F Spreafico
March 1978,
The Journal of pharmacology and experimental therapeutics,
A Vecchi, and
M Cairo, and
A Mantovani, and
M Sironi, and
F Spreafico
May 1975,
Cancer research,
A Vecchi, and
M Cairo, and
A Mantovani, and
M Sironi, and
F Spreafico
May 1979,
Cancer treatment reports,
A Vecchi, and
M Cairo, and
A Mantovani, and
M Sironi, and
F Spreafico
February 1978,
Cancer research,
A Vecchi, and
M Cairo, and
A Mantovani, and
M Sironi, and
F Spreafico
January 1983,
European journal of cancer & clinical oncology,
A Vecchi, and
M Cairo, and
A Mantovani, and
M Sironi, and
F Spreafico
July 1981,
Cancer research,
A Vecchi, and
M Cairo, and
A Mantovani, and
M Sironi, and
F Spreafico
November 1978,
Cancer research,
A Vecchi, and
M Cairo, and
A Mantovani, and
M Sironi, and
F Spreafico
January 1978,
Cancer treatment reports,
A Vecchi, and
M Cairo, and
A Mantovani, and
M Sironi, and
F Spreafico
September 1980,
Canadian journal of biochemistry,
